# McKESSON CORPORATION (MCK) FY2025 YTD Q3 P&L / Income Statement

- Company: McKESSON CORPORATION (MCK)
- Period: 2024-04-01 to 2024-12-31
- Filing: Q3 FY2025 10-Q, filed 2025-02-06, accession number 0000927653-25-000014
- Page: https://plicit.ai/financials/mck/fy2025-ytd-q3-income-statement
- Chart image: https://plicit.ai/charts/mck-fy2025-ytd-q3-income-statement-sankey.png

## Chart details: Revenue by Business Segment

Income statement for 2024-04-01 through 2024-12-31. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenues**: 268,228,000,000 US dollars
- **Cost of sales**: 258,544,000,000 US dollars
- **Gross profit**: 9,684,000,000 US dollars
- **Total operating expenses**: 6,853,000,000 US dollars
- **Operating income**: 2,831,000,000 US dollars
- **Other income (expense), net (calculated)**: 13,000,000 US dollars
- **Income before income taxes**: 2,844,000,000 US dollars
- **Income tax benefit (expense)**: 669,000,000 US dollars
- **Net income**: 2,175,000,000 US dollars
- **U.S. Pharmaceutical**: 244,551,000,000 US dollars
- **Prescription Technology Solutions**: 3,877,000,000 US dollars
- **Medical-Surgical Solutions**: 8,533,000,000 US dollars
- **International**: 11,260,000,000 US dollars
- **Corporate**: 7,000,000 US dollars
- **Selling, distribution, general, and administrative expenses**: 6,532,000,000 US dollars
- **Claims and litigation charges, net**: 108,000,000 US dollars
- **Restructuring, impairment, and related charges, net**: 213,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to McKESSON CORPORATION: $2.04 B; to noncontrolling interests: $140.00 M.